ArticleFrontiers in oncology2020
Development of an Immune-Related Gene Signature for Prognosis in Melanoma.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- A cuproptosis-related lncRNAs-based risk signature for predicting prognosis and immune status in glioma.Translational cancer research · 2026Article
- Targeting macrophage-associated core genes for prognostic prediction and therapeutic insights in bladder cancer.Discover oncology · 2026Article
- Machine Learning and Experimental Validation of m6A RNA Methylation Related Signatures for Risk Prediction, Diagnostic Biomarkers, and Immune Subtypes in Chronic Kidney Disease.Journal of inflammation research · 2026Article
- Macrophages in tertiary lymphoid structures promote apoptosis of ATF4-positive gastric cancer cells via IL18.Journal of translational medicine · 2025Article
- Evaluation of the clinical characteristics and potentially prognostic factors in HER2-positive breast cancer.Amino acids · 2025Article
- Role and mechanism of mitochondrial dysfunction‑related gene biomarkers in the progression of type 2 diabetes mellitus.Molecular medicine reports · 2025Article
- Identification of UBE2N as a biomarker of Alzheimer's disease by combining WGCNA with machine learning algorithms.Scientific reports · 2025Article
- The role of mitophagy-related genes in prognosis and immunotherapy of cutaneous melanoma: a comprehensive analysis based on single-cell RNA sequencing and machine learning.Immunologic research · 2025Article
- As a novel prognostic model for breast cancer, the identification and validation of telomere-related long noncoding RNA signatures.World journal of surgical oncology · 2024Article
- Multi-dimensional characterization of apoptosis in the tumor microenvironment and therapeutic relevance in melanoma.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Single-cell RNA sequencing unveils tumor heterogeneity and immune microenvironment between subungual and plantar melanoma.Scientific reports · 2024Article
- Nine-Gene Prognostic Signature Related to Gut Microflora for Predicting the Survival in Gastric Cancer Patients.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Comprehensive evaluation of cell death-related genes as novel diagnostic biomarkers for breast cancer.Heliyon · 2023Article
- Article
- TIGIT, a novel immune checkpoint therapy for melanoma.Cell death & disease · 2023Review
- Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma.Journal of personalized medicine · 2022Article
- Transcriptome-Wide m6A Methylome and m6A-Modified Gene Analysis in Asthma.Frontiers in cell and developmental biology · 2022Article
- Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma.Frontiers in genetics · 2022Article
- An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma.Frontiers in immunology · 2022Article
- The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma remains a potentially deadly malignant tumor. The incidence of melanoma continues to rise. Immunotherapy has become a new treatment method and is widely used in a variety of tumors. Original melanoma data were downloaded from TCGA. ssGSEA was performed to classify them. GSVA software and the "hclust" package were used to analyze the data. The ESTIMATE algorithm screened DEGs. The edgeR package and Venn diagram identified valid immune-related genes. Univariate, LASSO and multivariate analyses were used to explore the hub genes. The "rms" package established the nomogram and calibrated the curve. Immune infiltration data were obtained from the TIMER database. Compared with that of samples in the high immune cell infiltration cluster, we found that the tumor purity of samples in the low immune cell infiltration cluster was higher. The immune score, ESTIMATE score and stromal score in the low immune cell infiltration cluster were lower. In the high immune cell infiltration cluster, the immune components were more abundant, while the tumor purity was lower. The expression levels of TIGIT, PDCD1, LAG3, HAVCR2, CTLA4 and the HLA family were also higher in the high immune cell infiltration cluster. Survival analysis showed that patients in the high immune cell infiltration cluster had shorter OS than patients in the low immune cell infiltration cluster. IGHV1-18, CXCL11, LTF, and HLA-DQB1 were identified as immune cell infiltration-related DEGs. The prognosis of melanoma was significantly negatively correlated with the infiltration of CD4+ T cells, CD8+ T cells, dendritic cells, neutrophils and macrophages. In this study, we identified immune-related melanoma core genes and relevant immune cell subtypes, which may be used in targeted therapy and immunotherapy of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.